# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed b	<ul> <li>□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</li> <li>□ Definitive Proxy Statement</li> <li>☑ Definitive Additional Materials</li> </ul>	
		Diffusion Pharmaceuticals Inc.
		(Name of Registrant as Specified In Its Charter)
		Not Applicable
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
	No fee Fee co (1) (2) (3) (4) (5)	ing Fee (Check the appropriate box): e required. computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.  Title of each class of securities to which transaction applies: Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Proposed maximum aggregate value of transaction:  Total fee paid:
	Check	Amount Previously Paid:  Form, Schedule or Registration Statement No.:  Filing Party:  Date Filed:

## \*\*\* Exercise Your Right to Vote \*\*\*

## Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 17, 2020.

#### DIFFUSION PHARMACEUTICALS INC.

#### **Meeting Information**

Meeting Type: Annual Meeting
For holders as of: April 27, 2020
Date: June 17, 2020 Time: 9:00 AM, Eastern Time

Date: June 17,2020 Time: 9:00 AM, EasternTime Location: Meeting live via the Internet-please visit www.virtualshareholdermeeting.com/DFFN2020.

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/DFFN2020 and be sure to have the Information that is printed in the box marked by the arrow 

| XXXX XXXX XXXX XXXX | (located on the following page).

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

DIFFUSON PHARMACEUTICALS WC 1317 CARLTON AVENUE, SUITE 200 GHARLOTTESVILLE, VA 22502

## How to Access the Proxy Materials

#### Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT ANNUAL REPORT

How to View Online:

#### How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL\*: sendmaterial@proxyvote.com

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 4, 2020 to facilitate timely delivery.

### — How To Vote —

Please Choose One of the Following Voting Methods

#### Vote By Internet:

Before The Meeting

During The Meeting

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

**Vote by Phone:** You can vote by telephone by requesting a paper copy of the materials, which will include a proxy card that will provide instructions to vote these shares by proxy via telephone.

6308-P40902

#### Voting Items

## The Board of Directors recommends you vote FOR the following:

1. Election of the Directors

#### Nominees:

 01)
 David G. Kalergis
 04)
 John L. Gainer, Ph.D.

 02)
 Robert Adams
 05)
 Mark T. Giles

 03)
 Robert J. Cobuzzi, Ph.D.
 06)
 Alan Levin

#### The Board of Directors recommends you vote FOR the following proposals 2, 3 and 4.

- 2. To ratify the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2020.
- 3. To approve an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of the shares of the Company's common stock, par value \$0.001 per share, at a ratio of not less than one-to-two and not greater than one-to-twenty, with the exact ratio and effective time of the reverse stock split to be determined by our Board of Directors, if at all.
- To approve, on an advisory basis, the compensation of our named executive officers during the year ended December 31, 2019, as disclosed in the accompanying proxy statement.

NOTE: To transact such other business as may properly come before the meeting or any adjournment of the meeting.